Annals of Oncology Podcasts

ENGOT-en11/GOG-3053/KEYNOTE-B21: a phase III study of pembrolizumab or placebo + adj CHT +/- RT in patients with newly diagnosed, high-risk endometrial cancer

Article of the Month series

In this Article of the Month podcast Annals of Oncology Editor-in-Chief discusses the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial with Dr Toon Van Gorp of the Leuven Cancer Institute, Belgium. This randomised study evaluated adjuvant pembrolizumab plus chemotherapy for newly diagnosed, high-risk endometrial cancer, showing that while adjuvant pembrolizumab plus chemotherapy did not improve DFS in the intention-to-treat population, it did improve DFS in patients with dMMR tumours, as shown in prespecified subgroup analyses.

^{Van Gorp T, Cibula D, Lv W, et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024;35(11):968-980.} 
DOI: https://doi.org/10.1016/j.annonc.2024.08.2242

Published in November 2024

Intrapatient variation in PD-L1 expression and TMB and impact on ICI therapy in patients with NSCLC

Article of the Month series

In the latest Article of the Month podcast, Annals of Oncology Editor-in-Chief talks to Drs Mark Awad and Alessandro Di Federico (Dana-Farber Cancer Institute, Boston) about their recently published study assessing intrapatient variations in PD-L1 TPS and TMB and their clinical implications in patients with non-small-cell lung cancer.

^{Di Federico A, Alden SL, Smithy JW, et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann Oncol. 2024;35(10):902-913.} 
DOI: https://doi.org/10.1016/j.annonc.2024.06.014

Published in October 2024

5-yr analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

Article of the Month series

Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. In this podcast, Annals of Oncology Editor-in-Chief Tom Powles, discusses the 5-year outcomes from the phase II NeoCombi trial with Professor Georgina Long, of the Melanoma Institute Australia, The University of Sydney.

^{Menzies AM, Lo SN, Saw RPM, et al. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma. Ann Oncol. 2024;35(8):739-746.} 
DOI: https://doi.org/10.1016/j.annonc.2024.05.002

Published in August 2024

IMpassion132 trial of chemo +/- atezolizumab for early relapsing unresectable LA/metastatic TNBC

Article of the Month series

Data on outcomes in patients with rapidly relapsing TNBC are scarce. In this podcast Annals of Oncology Editor-in-Chief discusses the IMpassion132 trial with author Prof. Rebecca Dent, of the Division of Medical Oncology, National Cancer Center, Singapore. IMpassion132 trial was designed to evaluate the anti-PD-L1 agent atezolizumab combined with chemotherapy specifically in patients with TNBC relapsing within 12 months of standard-of-care chemotherapy or surgery for eTNBC.

^{Dent R, André F, Gonçalves A, et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024;35(7):630-642.}
DOI: https://doi.org/10.1016/j.annonc.2024.04.001

Published in July 2024

Ipi/nivo in patients with advanced HCC previously treated with sorafenib: CheckMate 040 5-yr results

Article of the Month series

Nivolumab plus ipilimumab have demonstrated promising clinical activity and durable responses in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC) in the CheckMate 040 study. In this podcast, Prof. Ignacio Melero, of the Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain, discusses the recently published 5-year results from this cohort with Annals of Oncology Editor-in-Chief Prof. Tom Powles.

^{Melero I, Yau T, Kang YK, Tschaika M, Hsu C, El-Khoueiry AB, et al. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. Ann Oncol. 2024;35(6):537-548.}
DOI: https://doi.org/10.1016/j.annonc.2024.03.005

Published in June 2024

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

Article of the Month series

Annals of Oncology Editor-in-Chief Tom Powles talks to Dr Giorgio Bogani, of the Istituto Nazionale dei Tumori di Milano, Italy. They discuss the recently published study considering recent phase III trials that investigated the role of immunotherapy in the first-line setting for advanced or recurrent endometrial cancer.

^{Bogani G, Monk BJ, Powell MA, et al. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024;35(5):414-428.}
DOI: https://doi.org/10.1016/j.annonc.2024.02.006

Published in May 2024

B-cell infiltration is associated with survival following PD-1 inhibition in HNSCC

Article of the Month series

Annals of Oncology Editor in Chief Tom Powles talks to Prof. Amanda Psyrri, of the National Kapodistrian University of Athens, Greece. They discuss her recently published study that aimed to investigate the association of immune cell-related biomarkers in the tumor and tumor microenvironment with PD-1 checkpoint inhibitors’ outcomes in patients with metastatic head and neck squamous cell cancer (HNSCC).

^{Gavrielatou N, Fortis E, Spathis A, et al. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Ann Oncol. 2024;35(4):340-350.}
DOI: https://doi.org/10.1016/j.annonc.2023.12.011

Published in April 2024

Response-guided neoadjuvant sacituzumab govitecan for localized TNBC

Article of the Month series

Sacituzumab govitecan (SG), a novel antibody–drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). In this podcast, Annals of Oncology Editor-in-Chief Prof. Tom Powles, discusses with Prof. Aditya Bardia the NeoSTAR trial, the subject of Annals of Oncology's article of the month for March, an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG for localized TNBC.

^{L. M. Spring, S. M. Tolaney, G. Fell, et al. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Annals of Oncology. 2024;35(3):293-301.}
DOI: https://doi.org/10.1016/j.annonc.2023.11.018

Published in March 2024

ctDNA and radiological tumor volume and risk of relapse with resected, early-stage NSCLC

Article of the Month series

Predicting relapse and overall survival (OS) in early-stage non-small-cell lung cancer (NSCLC) patients remains challenging. In this podcast, Professor John Heymach, University of Texas MD Anderson Cancer Center, Huston, USA, discusses, with Annals of Oncology Editor-in-Chief, Tom Powles, a study in which serial plasma samples from early-stage NSCL patients who underwent surgical resections were analysed and ctDNA assessed using a next-generation sequencing liquid biopsy assay, and tumor volume measured using a computed tomography-based three-dimensional annotation to assess risk.

^{Tran HT, Heeke S, Sujit S, et al. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Annals of Oncology. 2024;35(2):183-189.}
DOI: doi.org/10.1016/j.annonc.2023.11.008

Published in February 2024

The DAD trial: sacituzumab govitecan+enfortumab vedotin for metastatic urothelial carcinoma

Article of the Month series

Dr Brad McGregor, of the Dana Farber Cancer Institute, discusses the DAD phase I trial with Annals of Oncology Editor-in-Chief, Prof. Tom Powles. This is the first trial in any malignancy to show that antibody-drug conjugates could be safely given in combination.

^{McGregor BA, Sonpavde GP, Kwak L et al. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol 2023; 35: 91-97.
DOI: https://doi.org/10.1016/j.annonc.2023.09.3114}

Published in January 2024

Genome instability and success of checkpoint inhibitors

Dr Sarah Derks, of Amsterdam UMC, discusses her recent editorial in Annals of Oncology on the report of Shitara et al. who presented an exploratory analysis from the KEYNOTE-061 trial evaluating the association of tTMB with PD-L1 and MSI-H and their relationship with clinical outcomes in patients with advanced gastric/GEJ cancer receiving second-line pembrolizumab or paclitaxel.

^{Derks S. Genome instability and success of checkpoint inhibitors: form and levels matter. Ann Oncol 2021; 32: 1073-1074.
Shitara K et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol 2021; 32: 1127-1136.}

Published in September 2021

Immunotherapy trials for metastatic triple-negative breast cancer

Dr Marleen Kok, of the Netherlands Cancer Institute, discusses her recent editorial, written with Dr Leonie Voorwerk, on the results of the IMpassion130 and IMpassion131 trials of immunotherapy in unresectable, locally advanced, or metastatic triple-negative breast cancer, results of which are both published in the August issue of Annals of Oncology.

Published in September 2021

IgE blockade in the management of eosinophil-associated recalcitrant pruritus

Professor Ralf Gutzmer, of the Skin Cancer Center Minden, discusss his recent editorial, with colleagues, on a the recently published study of Barrios et al, which sought to evaluate the efficacy and safety of IgE blockade with omalizumab in cancer patients with refractory pruritus-associated cutaneous adverse events related to checkpoint inhibitors and anti-HER2 agents.

^{Gutzmer R, Sibaud V, Hassel JC. IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy. Ann Oncol 2021; 32: 696-697.
Barrios DM, Phillips GS, Geisler AN et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 2021; 32: 736-745.}

Published in July 2021

Cabazitaxel vs abiraterone or enzalutamide in poor prognosis metastatic CRPC

Professor Ronald de Wit, of the Erasmus MC Cancer Institute, Rotterdam, discusses the editorial he wrote with colleagues on the recent publication of Annala et al.They reported on a randomised, phase II study evaluating cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer.

^{Annala M, Fu S, Bacon JVW et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol 2021; 32: 896-905.
Robbrecht DHJ, Buck SAJ, de Wit R. Outcomes of treatment choices in poor prognosis prostate cancer: notagainst all odds. Ann Oncol 2021; 32: 831-832.}

Published in July 2021